Skip to navigation menu Skip to content
High Priority Alert

We are experiencing extremely high demand in our Emergency Department. Learn more.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines. Learn more.

What Is DIPG?

Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are tumors for which there is no cure.

Because of where these tumors are located in the brain or spinal cord, complete resection is not possible. Radiation and chemotherapy may improve symptoms and extend life, but the average survival remains approximately 11 months.

The DIPG Research Program at Seattle Children’s focuses on DIPG, DMG and other life-threatening central nervous system (CNS) tumors through:

  • Comprehensive and coordinated clinical care designed to address each child’s needs and circumstances
  • Innovative laboratory studies that help us better understand these tumors, predict their behavior and treat them more effectively
  • Clinical trials of new therapies, including CAR T-cell immunotherapy

Find out more information about the DIPG Research Program.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies